HC Wainwright reaffirmed their buy rating on shares of Innate Pharma (NASDAQ:IPHA – Free Report) in a research note published on Friday morning, Benzinga reports. HC Wainwright currently has a $11.50 target price on the stock.
Innate Pharma Price Performance
Innate Pharma stock opened at $2.17 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 3.73 and a current ratio of 3.73. Innate Pharma has a 1 year low of $1.81 and a 1 year high of $3.15. The company’s 50-day moving average is $2.21 and its two-hundred day moving average is $2.40.
Innate Pharma Company Profile
Read More
- Five stocks we like better than Innate Pharma
- Using the MarketBeat Dividend Tax Calculator
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How to Invest in Small Cap Stocks
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.